Applied Therapeutics (NASDAQ:APLT – Get Rating) is scheduled to be announcing its earnings results on Monday, March 20th.
Applied Therapeutics Stock Up 5.5 %
Shares of NASDAQ:APLT opened at $0.95 on Friday. The company has a market cap of $45.76 million, a price-to-earnings ratio of -0.29 and a beta of 1.90. Applied Therapeutics has a fifty-two week low of $0.50 and a fifty-two week high of $2.73. The firm’s 50-day simple moving average is $1.02 and its 200-day simple moving average is $0.95.
Institutional Trading of Applied Therapeutics
A number of institutional investors have recently added to or reduced their stakes in APLT. FMR LLC boosted its holdings in Applied Therapeutics by 343.6% during the second quarter. FMR LLC now owns 4,007,283 shares of the company’s stock worth $3,800,000 after buying an additional 3,103,990 shares in the last quarter. Point72 Asset Management L.P. boosted its holdings in Applied Therapeutics by 11.2% during the second quarter. Point72 Asset Management L.P. now owns 2,835,000 shares of the company’s stock worth $2,688,000 after buying an additional 286,000 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in Applied Therapeutics by 1,503.4% during the first quarter. Renaissance Technologies LLC now owns 282,200 shares of the company’s stock worth $595,000 after buying an additional 264,600 shares in the last quarter. Millennium Management LLC boosted its holdings in Applied Therapeutics by 233.8% during the second quarter. Millennium Management LLC now owns 360,814 shares of the company’s stock worth $342,000 after buying an additional 252,718 shares in the last quarter. Finally, Two Sigma Advisers LP boosted its holdings in Applied Therapeutics by 121.7% during the third quarter. Two Sigma Advisers LP now owns 249,200 shares of the company’s stock worth $232,000 after buying an additional 136,800 shares in the last quarter. Hedge funds and other institutional investors own 62.94% of the company’s stock.
About Applied Therapeutics
Applied Therapeutics, Inc is a clinical-stage biopharmaceutical company which engages in the development of a pipeline of novel products. It is targeting treatments for central nervous system rare diseases and diabetic complications. The company was founded by Shoshana Shendelman on January 20, 2016 and is headquartered in New York, NY.
- Get a free copy of the StockNews.com research report on Applied Therapeutics (APLT)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Applied Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.